Vaxigripetra

Phase 1Biologic

CCopenhagen Respiratory Research

Vaxigripetra is one of 4 biologic programs targeting Immunology. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunologyActive, not recruiting

ImmunologyPhase 1

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Immunology

#DrugCompanyPhaseTrials

Nonavalent HPV Vaccine

XXiamen University

Phase 3

1 2

Trivalent Split Inf

Sanofi

Phase 3

1 3

Flumist

AstraZeneca

Phase 1

1 4

Vaxigripetra

CCopenhagen Respiratory Research

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunology1 trial

Vaccine Pandemic Preparedness Through Airway Immunology Characterization

Active, not recruiting·CCopenhagen Respiratory Research·Phase 1·NCT05921448·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vaxigripetra. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vaxigripetra compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vaxigripetra. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Copenhagen Respiratory Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CCopenhagen Respiratory Research

Vaxigripetra

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunology1 trial

References

Drug Info

Quick Facts

Related News